Biological drugs for the treatment of psoriasis in a public health system

Revista de Saude Publica

Volumn 48, Issue 4, 2014, Pages 651-661

  Lopes, Luciane Cruz ^a   do Nascimento Silveira, Miriam Sanches ^a   de Camargo, Iara Alves ^a,b   Barberato Filho, Silvio ^a   de Sa´ Del Fiol, Fernando ^a   Osoriode Castro, Claudia Garcia Serpa ^c  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b SUVIS Casa Verde   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antibodies, monoclonal, therapeutic use; Equity in access; Judicial decisions; Pharmaceutical services, legislation jurisprudence; Psoriasis

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; BRAZIL; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE DELIVERY; HUMAN; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; PATIENT RIGHT; PSORIASIS; PUBLIC HEALTH; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT RIGHTS; PSORIASIS; PUBLIC HEALTH; YOUNG ADULT;

EID: 84906975041     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0034-8910.2014048005109     Document Type: Article

References (18)

1. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274-85. DOI:10.1111/j.1365-2133.2008.08673.x
2. Chieffi AL, Barata RCB. Ac¸ões judiciais: estrate´gia da indu´stria farmaceˆutica para introduc¸ão de novos medicamentos. Rev Saude Publica. 2010;44(3):421-9. DOI:10.1590/S0034-89102010000300005
3. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-50. DOI:10.1016/j.jaad.2010.09.734
4. Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, et al. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol. 2012;34(4):548-60. DOI:10.3109/08923973.2011.653646
5. Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am. 2010;94(4):791-804, xi-ii. DOI:10.1016/j.mcna.2010.03.001
6. Lopes LC, Barberato-Filho S, Costa AC, Osoriode-Castro CGS. Uso racional de medicamentos antineopla´sicos e ac¸ões judiciais no Estado de São Paulo. Rev Saude Publica. 2010;44(4):620-8. DOI:10.1590/S0034-89102010000400005
7. Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol. 2012;26(11):1331-44. DOI:10.1111/j.1468-3083.2012.04492.x
8. Macedo EI, Lopes LC, Barberato-Filho S. Ana´lise te´cnica para a tomada de decisão do fornecimento de medicamentos pela via judicial. Rev Saude Publica. 2011;45(4):706-13. DOI:10.1590/S0034-89102011005000044
9. Mazurek J, Jahnz-Ro´zyk K. The variety of types of adverse side-effects during treatment with biological drugs. Int Rev Allergol Clin Immunol Family Med. 2012;18(1):34-40.
10. Monteiro CA, Moura EC, Jaime PC, Lucca A, Florindo AA, Figueiredo ICR, et al. Monitoramento de fatores de risco para doenc¸as croˆnicas por entrevistas telefoˆnicas. Rev Saude Publica. 2005;39(1):47-57. DOI:10.1590/S0034-89102005000100007
11. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912-20. DOI:10.1111/j.1398-9995.2006.01058.x
12. Rustin MHA. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167(Suppl 3):3-11. DOI:10.1111/j.1365-2133.2012.11208.x
13. Sa´nchez-Regaña M, Dilme E, Puig L, Bordas X, Carrascosa JM, Ferran M, et al. Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group. Actas Dermosifiliogr. 2010;101(2):156-63. DOI:10.1016/S1578-2190(10)70602-8
14. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011;16(2):CD008794. DOI:10.1002/14651858.CD008794.pub2
15. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019. DOI:10.1111/j.1365-2133.2009.09505.x
16. Vieira FS, Zucchi P. Distortions to national drug policy caused by lawsuits in Brazil. Rev Saude Publica. 2007;41(2):214-22. DOI:10.1590/S0034-89102007000200007
17. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810-20. DOI:10.1111/j.1476-5381.2010.00702.x
18. Zemkova´ M, Jebavy` L, Kotla´rova´ J, Vlcek J, Meyboom RH. The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification. Folia Biol (Praha). 2007;53(4):146-55.